Complete financial analysis of Otonomy, Inc. (OTIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Otonomy, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oi Electric Co., Ltd. (6822.T) Income Statement Analysis – Financial Results
- Lode-Star Mining Inc. (LSMG) Income Statement Analysis – Financial Results
- Chung Hung Steel Corporation (2014.TW) Income Statement Analysis – Financial Results
- Kenedix Office Investment Corporation (8972.T) Income Statement Analysis – Financial Results
- Linde India Limited (LINDEINDIA.NS) Income Statement Analysis – Financial Results
Otonomy, Inc. (OTIC)
About Otonomy, Inc.
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 125.00K | 273.00K | 600.00K | 745.00K | 1.24M | 683.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 370.00K | 1.19M | 912.00K | 946.00K | 3.10M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -245.00K | -915.00K | -312.00K | -201.00K | -1.86M | -981.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -196.00% | -335.16% | -52.00% | -26.98% | -150.65% | -143.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 34.67M | 28.00M | 32.81M | 31.84M | 42.70M | 60.72M | 38.76M | 31.80M | 16.34M | 8.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.71M | 14.58M | 11.69M | 20.01M | 46.84M | 49.78M | 23.21M | 7.84M | 3.51M | 2.41M |
| Other Expenses | 0.00 | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | -14.00K | 3.71M |
| Operating Expenses | 49.38M | 42.57M | 44.50M | 51.85M | 89.54M | 110.50M | 61.98M | 39.64M | 19.85M | 10.93M |
| Cost & Expenses | 49.75M | 43.76M | 45.41M | 52.80M | 92.64M | 112.16M | 61.98M | 39.64M | 19.85M | 10.93M |
| Interest Income | 43.00K | 326.00K | 1.72M | 1.69M | 1.27M | 899.00K | 419.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.60M | 1.57M | 1.59M | 4.00K | 0.00 | 0.00 | 0.00 | 39.00K | 2.53M | 444.00K |
| Depreciation & Amortization | 856.00K | 1.06M | 1.15M | 1.19M | 1.29M | 708.00K | 358.00K | 213.00K | 257.00K | 192.00K |
| EBITDA | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.61M | -7.03M |
| EBITDA Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -49.63M | -43.49M | -44.81M | -52.05M | -91.40M | -111.48M | -61.98M | -39.64M | -19.85M | -10.93M |
| Operating Income Ratio | -39,700.00% | -15,929.30% | -7,467.83% | -6,986.98% | -7,394.90% | -16,322.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.56M | -1.24M | 132.00K | 1.69M | 1.27M | 898.00K | 308.00K | -3.24M | 291.00K | 3.36M |
| Income Before Tax | -51.18M | -44.73M | -44.68M | -50.37M | -90.13M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Income Before Tax Ratio | -40,944.80% | -16,384.98% | -7,445.83% | -6,760.81% | -7,292.07% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -856.00K | -1.06M | -1.15M | -1.19M | -1.29M | -708.00K | -358.00K | -213.00K | 2.51M | 4.15M |
| Net Income | -50.33M | -43.67M | -43.53M | -49.18M | -88.84M | -110.58M | -61.67M | -42.88M | -19.56M | -7.57M |
| Net Income Ratio | -40,260.00% | -15,995.97% | -7,254.33% | -6,601.61% | -7,187.78% | -16,190.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| EPS Diluted | -0.79 | -1.07 | -1.42 | -1.61 | -2.93 | -3.69 | -2.57 | -5.46 | -1.70 | -0.66 |
| Weighted Avg Shares Out | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
| Weighted Avg Shares Out (Dil) | 63.44M | 40.85M | 30.73M | 30.61M | 30.30M | 29.96M | 23.95M | 7.85M | 11.47M | 11.47M |
Otonomy, Inc. (OTIC) CEO David Weber on Q1 2021 Results - Earnings Call Transcript
Otonomy, Inc. (OTIC) CEO David Weber on Q1 2021 Results - Earnings Call Transcript
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update...
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency AAV-mediated gene therapy rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 8,298,890 shares of its...
Otonomy Announces Pricing of $30.1 Million Public Offering
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 6,288,890 shares of its common stock...
Otonomy Announces Proposed Public Offering
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock. All shares...
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of previously disclosed clinical results from the successful OTO-313 Phase 1/2 trial at...
Are Options Traders Betting on a Big Move in Otonomy (OTIC) Stock?
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Otonomy to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management will participate in three upcoming virtual conferences:
Source: https://incomestatements.info
Category: Stock Reports